Protective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in rats

Basit Öğe Kaydı
dc.authorscopusid7006356462
dc.authorscopusid7403697089
dc.authorscopusid23060179500
dc.authorscopusid24436194200
dc.authorscopusid6507959144
dc.authorscopusid36023238400
dc.authorwosidAktas, Cevat/D-8468-2011
dc.contributor.authorKanter, Mehmet
dc.contributor.authorSen, Saniye
dc.contributor.authorDönmez, Salim
dc.contributor.authorAktaş, Cevat
dc.contributor.authorÜstündağ, Sedat
dc.contributor.authorErboğa, Mustafa
dc.date.accessioned2022-05-11T14:41:24Z
dc.date.available2022-05-11T14:41:24Z
dc.date.issued2010
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Histoloji ve Embriyoloji Ana Bilim Dalı
dc.description.abstractThe aim of this study was designed to investigate the possible beneficial effects of the angiotensin (ang) II T-1 (AT(1)) receptor blocker, irbesartan (Irb), and the alpha lipoic acid (ALA) in streptozotocin (STZ)-induced diabetic nephropathy (DNP) in rats. The rats were randomly allotted into one of five experimental groups: A, control; B, diabetic untreated; C, diabetic treated with Irb; D, diabetic treated with ALA; and E, diabetic treated with Irb + ALA; each group contains 10 animals. B, C, D, and E groups received STZ. Diabetes was induced in four groups by a single intraperitoneal injection of STZ (50 mg/kg, freshly dissolved in 5 mmol/L citrate buffer, pH 4.5). The rats in Irb-, ALA-, and Irb + ALA-treated groups were given Irb (5 mg/kg), ALA (in a dose of 3 mg/kg), and Irb + ALA (in a dose of 2.5 + 1.5 mg/kg) once a day orally by using intragastric intubation for 12 weeks starting 2 days after STZ injection, respectively. Treatment with ALA and especially Irb reduced the glomerular size; thickening of capsular, glomerular, and tubular basement membranes; increased amounts of mesangial matrix and tubular dilatation as compared with diabetic-untreated rats. Notably, the better effects were obtained when Irb and ALA were given together. We conclude that Irb, ALA, and especially Irb + ALA therapy causes renal morphologic improvement after STZ-induced diabetes in rats. We believe that further preclinical research into the utility of Irb and ALA treatment, alone or its combination, may indicate its usefulness as a potential treatment in DNP.</.
dc.identifier.doi10.3109/08860221003646360
dc.identifier.endpage505
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue4en_US
dc.identifier.pmid20446791
dc.identifier.scopus2-s2.0-77952174536
dc.identifier.scopusqualityQ2
dc.identifier.startpage498
dc.identifier.urihttps://doi.org/10.3109/08860221003646360
dc.identifier.urihttps://hdl.handle.net/20.500.11776/9171
dc.identifier.volume32
dc.identifier.wosWOS:000277388400016
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAktaş, Cevat
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofRenal Failure
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectirbesartan
dc.subjectalpha lipoic acid
dc.subjectTGF-beta(1)
dc.subjectiNOS
dc.subjectdiabetic nephropathy
dc.subjectGrowth-Factor-Beta
dc.subjectConverting Enzyme-Inhibition
dc.subjectOxidative Stress
dc.subjectKidney-Disease
dc.subjectNigella-Sativa
dc.subjectCell Damage
dc.subjectExpression
dc.subjectReceptor
dc.subjectMellitus
dc.titleProtective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in rats
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
9171.pdf
Boyut:
1.3 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu